EPOCAN
Gaining sage on the Epoetins' saga: assessing long term risks and advancing towards better Epoetin driven treatment modalities
| Coordinatore | TEL AVIV UNIVERSITY
Organization address
address: RAMAT AVIV contact info |
| Nazionalità Coordinatore | Israel [IL] |
| Totale costo | 3˙927˙556 € |
| EC contributo | 2˙995˙103 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-10-01 - 2014-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TEL AVIV UNIVERSITY
Organization address
address: RAMAT AVIV contact info |
IL (TEL AVIV) | coordinator | 350˙400.00 |
| 2 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 301˙680.00 |
| 3 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 298˙160.00 |
| 4 |
UNIVERSIDAD AUTONOMA DE MADRID
Organization address
address: CALLE EINSTEIN, CIUDAD UNIV CANTOBLANCO RECTORADO 3 contact info |
ES (MADRID) | participant | 291˙200.00 |
| 5 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 281˙600.00 |
| 6 |
VETERINAERMEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: Veterinaerplatz 1 contact info |
AT (VIENNA) | participant | 241˙173.60 |
| 7 |
UNIVERSITAET DUISBURG-ESSEN
Organization address
address: UNIVERSITAETSSTRASSE 2 contact info |
DE (ESSEN) | participant | 240˙600.00 |
| 8 |
QUEEN'S UNIVERSITY BELFAST
Organization address
address: University Road contact info |
UK (BELFAST) | participant | 233˙520.00 |
| 9 |
DEUTSCHES HERZZENTRUM MUNCHEN
Organization address
address: Lazarettstrasse 36 contact info |
DE (MUNICH) | participant | 180˙520.00 |
| 10 |
ALDEVRON FREIBURG GMBH
Organization address
address: WALTERSHOFENER STRASSE 17 contact info |
DE (FREIBURG) | participant | 162˙471.60 |
| 11 |
WINZSOFT (ISRAEL) LTD
Organization address
address: Beit Hillel 3 contact info |
IL (TEL AVIV-JAFFO) | participant | 161˙280.00 |
| 12 |
MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
AT (INNSBRUCK) | participant | 132˙038.40 |
| 13 |
OSM-DAN LTD.
Organization address
address: Pekeris Street 4 contact info |
IL (REHOVOT) | participant | 120˙460.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'EpoCan aims to develop and implement a comprehensive interdisciplinary strategy to assess the long-term risks of erythropoietin (EPO) and its derivatives (epoetins) on tumour growth progression and thromboembolic events in cancer patients, cardiovascular events, and the development of cancer in chronic kidney disease. Approximately 400,000 patients across Europe receive epoetins treatment each year. Recent meta-analysis data have raised concerns over increased mortality in some patient groups. Hence the urgent need to evaluate the risk-benefit ratio of epoetin treatment and its potential long-term effects. EpoCan brings together a multidisciplinary consortium of 12 world leading academic, industrial and medical partners, with long-standing, complementary expertise in haemostasis, oncology and EPO biology. EpoCan aims to (1) Identify, detect and measure possible long-term hazards of epoetin treatment; (2) Develop novel prognostic tools and new complementary therapeutic reagents: (3) Evaluate the risk-benefit ratio to pave the way for new safety and efficacy criteria. EpoCan will: (a) Utilize a wide array of cellular models to thoroughly analyze EPO/EPO receptor(EPO-R)interaction and signalling, to define the relationship between EPO-R expression in tumour samples and the clinical outcome in cancer patients; (b) Establish and test new, personalized, predictive tools (EPO-R peptide antagonists, novel specific anti-EPO-R monoclonal antibodies, thromboembolic tests); (c) Create new murine models as hosts for tumour implantation subjected to EPO and derivatives established above; (d) Screen and analyze clinical databases; (e) Define models to predict hazardous versus safe/beneficial roles of epoetins in the treatment of cancer and kidney failure associated anaemia. Data obtained will be integrated into coherent models using novel computational algorithms developed for EpoCan. Results are expected to have broad ramifications, with special relevance for clinical oncology.'
Altri progetti dello stesso programma (FP7-HEALTH)
EUROGENTEST2 (2011)
"Genetic testing in Europe - Network for the further development, harmonization, validation and standardization of services"
Read MoreMERCURIC (2013)
A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients
Read More